title: Antihypertensive utility of perindopril in a large, general practice-based clinical trial.
abstract: The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.
authors.affiliation: Division of Hypertension, University of Michigan, Ann Arbor, MI 48109, USA.
authors.forename: Stevo
authors.initials: S
authors.lastname: Julius
authors.forename: Jay N
authors.initials: JN
authors.lastname: Cohn
authors.forename: Joel
authors.initials: J
authors.lastname: Neutel
authors.forename: Michael
authors.initials: M
authors.lastname: Weber
authors.forename: Prasad
authors.initials: P
authors.lastname: Turlapaty
authors.forename: Yannan
authors.initials: Y
authors.lastname: Shen
authors.forename: Victor
authors.initials: V
authors.lastname: Dong
authors.forename: Alicia
authors.initials: A
authors.lastname: Batchelor
authors.forename: Hjalmar
authors.initials: H
authors.lastname: Lagast
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005194:Family Practice; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000009:adverse effects / Q000627:therapeutic use*; D012449:Safety; D016896:Treatment Outcome; D014481:United States
chemical_list: D000959:Antihypertensive Agents; D020913:Perindopril